Anuh Pharma's FY26 revenue rose 16.6% but profit fell 13.3%
The divergence between topline growth and bottomline decline is the standout signal in an otherwise routine annual results filing. Dividend recommended at ₹1.50 per share.
— 3 earlier stories on Anuh Pharma Ltd. →What's new
- FY26 revenue up 16.6% but PAT down 13.3% vs prior year.
- Board recommended ₹1.50/share dividend for FY26.
- Routine reappointments of directors, auditors, and promoter reclassification approved.
Why it matters
Revenue growth without profit expansion typically points to margin compression or higher costs. For a pharma company, this divergence merits attention as it may signal input cost pressures or pricing weakness. The dividend hike could be an attempt to offset investor disappointment from the profit decline.
What we're watching
- Whether margin trends improve in Q1FY27.
- Any management commentary on cost drivers or growth drivers.
- The outcome of promoter reclassification and its governance implications.
The full read
Anuh Pharma reported a 16.6% rise in annual revenue to an undisclosed amount, but profit after tax dropped 13.3% for the year ended March 2026. That is the headline number that jumps out from an otherwise standard audited results filing. The board also recommended a dividend of ₹1.50 per share, a modest increase from prior levels, and approved routine items such as director reappointments and the appointment of an internal auditor and cost auditor. The divergence between revenue and profit is the real story here. It suggests the company is growing but not efficiently, either because input costs are rising or pricing power is weakening. For investors, the dividend offers some return but does not address the underlying margin question. The next quarterly numbers will be the first test of whether this is a one-off or a trend.